Kallistem is a biotech company specialized in spermatogenesis. The company was founded in 2012 with the objective to anticipate and treat male infertility. It promotes a technology and expertise developed by Philippe Durand and Marie-Helene Perrard, two internationally renowned scientists in the field of the reproductive biology and more specially in in vitro spermatogenesis.
Kallistem has developed, in collaboration with its partners, original and innovating technologies of germinal cell culture for male fertility preservation and the treatment of male infertility.
Kallistem has developed Bio-AlteR®, a predictive 3D cell-based screening platform, to explore much earlier the impact on testicular function following exposure to a range of chemicals, (including pharmaceutical or agrochemical compounds, cosmetics, endocrine disruptors and environmental contaminants).
Bio-AlteR® can be used to provide mechanistic insight and study molecules for testicular toxicity risk
Kallistem has not received any reviews.
Kallistem has not received any endorsements.